This week's episode of “The Readout LOUD” is all about health politics, including Marty Makary's departure as FDA ...

The Supreme Court on Thursday preserved women’s access to the abortion drug mifepristone, rejecting lower-court ...

Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout ...

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.

CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates ...

The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas ...

At MIT, research has shrunk 10% from a year ago, and the school expects a persistent drop in graduate admissions.

Biogen reported mixed results from a mid-stage clinical trial investigating a treatment for Alzheimer’s disease that targets ...

Leaders want the next FDA commissioner to be someone who can rebuild trust, focus on food policy, and drive drug-approval ...

The next FDA leader, how the CDC is responding to hantavirus, and more health news from Morning Rounds ...

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...

Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the ...